Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
1 Vues
• 08/09/23
0
0
Intégrer
administrator
Les abonnés
Basem William, MD, MRCP, FACP associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive/
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires